Hetzer Roland, Alexi-Meskishvili Vladimir, Weng Yuguo, Hübler Michael, Potapov Evgenij, Drews Thorsten, Hennig Ewald, Kaufmann Friedrich, Stiller Brigitte
Deutsches Herzzentrum, Berlin, Germany.
Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2006:99-108. doi: 10.1053/j.pcsu.2006.02.012.
The pediatric-size pneumatically driven pulsatile extracorporeal ventricular assist device (VAD) Berlin Heart EXCOR (Berlin Heart Mediprodukt GmbH, Berlin, Germany) was introduced into clinical practice by the German Heart Institute Berlin in 1992. Until July 1, 2005, Berlin Heart EXCOR systems have been used for circulatory support in 68 children up to 18 years of age with severe circulatory failure resistant to pharmacologic therapy. These were patients suffering from cardiomyopathy, fulminant myocarditis, end-stage congenital cardiac defects, and acute heart failure following congenital heart surgery. Mean VAD support time was 35 days (range, 0 to 420 days). Forty-two patients (62%) survived to transplantation or after weaning; 37 patients (54%), including eight infants, were discharged home. These results in patients with very advanced disease have improved significantly in recent years because of technical developments and growing experience in the treatment of patients on the device, in postoperative care and optimal timing for VAD implantation. Timely implantation of the Berlin Heart EXCOR in the course of progressive heart failure now appears to be justified because the system has undergone the necessary modifications and the accumulation of clinical knowledge has made its use highly reliable and safe.
儿童尺寸的气动搏动性体外心室辅助装置(VAD)柏林心脏EXCOR(德国柏林柏林心脏医疗产品有限公司)于1992年由柏林德国心脏研究所引入临床实践。截至2005年7月1日,柏林心脏EXCOR系统已用于68名18岁以下患有严重循环衰竭且对药物治疗耐药的儿童的循环支持。这些患者患有心肌病、暴发性心肌炎、终末期先天性心脏缺陷以及先天性心脏手术后的急性心力衰竭。平均VAD支持时间为35天(范围为0至420天)。42名患者(62%)存活至移植或撤机后;37名患者(54%),包括8名婴儿,出院回家。近年来,由于技术发展以及在使用该装置治疗患者、术后护理和VAD植入最佳时机方面经验的增加,这些患有非常严重疾病的患者的治疗结果有了显著改善。现在,在进行性心力衰竭过程中及时植入柏林心脏EXCOR似乎是合理的,因为该系统已经进行了必要的改进,并且临床知识的积累使其使用高度可靠和安全。